While significant advances have been made in lowering detection limits, accelerating assay times, and demonstrating applicability in clinical samples, more research is needed to transition highly sensitive laboratory-based NSE immunosensing tools into commercial point-of-care devices for early SCLC diagnosis. Here, ENO2 is linked to small cell lung carcinoma.